thumbnail
Global MarketsUS looks to 2032 as cut-off from Chinese biomanufacturing relianceUS looks to 2032 as cut-off from Chinese biomanufacturing reliance
A revised version of the US BIOSECURE Act will give US biopharma firms until 2032 to sever ties with Chinese suppliers. For WuXi Biologics, this could lead to share buybacks, privatization, or an all-out sale says one analyst.